The BiTE (bispecific T‐cell engager) platform: Development and future potential of a targeted immuno‐oncology therapy across tumor types-Reference-Cited by-同舟云学术

The BiTE (bispecific T‐cell engager) platform: Development and future potential of a targeted immuno‐oncology therapy across tumor types

Published:2020-05-13 Issue:14 Volume:126 Page:3192-3201
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Einsele Hermann¹,Borghaei Hossein²^ORCID,Orlowski Robert Z.³,Subklewe Marion⁴,Roboz Gail J.⁵,Zugmaier Gerhard⁶,Kufer Peter⁶,Iskander Karim⁷,Kantarjian Hagop M.⁸^ORCID

Affiliation:

1. Department of Internal Medicine II Universität Würzburg Würzburg Germany

2. Department of Hematology/Oncology Fox Chase Cancer Center Philadelphia Pennsylvania

3. Department of Lymphoma and Myeloma The University of Texas MD Anderson Cancer Center Houston Texas

4. Department of Medicine III University HospitalLudwig‐Maximilians University Munich Munich Germany

5. Weill Cornell Medicine Division of Hematology and Oncology The New York Presbyterian Hospital New York New York

6. Amgen Research (Munich) GmbH Munich Germany

7. Amgen Inc. Thousand Oaks California

8. Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas

Funder

Amgen

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.32909

Reference73 articles.

1. Cancer immunotherapy: the beginning of the end of cancer?

2. Immunotherapy in hematologic malignancies: past, present, and future

3. Immuno-Oncology: Emerging Targets and Combination Therapies

4. The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment

5. A Review of Efficacy and Safety of Checkpoint Inhibitor for the Treatment of Acute Myeloid Leukemia

Cited by 138 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An open source in silico workflow to assist in the design of fusion proteins;Computational Biology and Chemistry;2024-12

2. Recent Advancements in Cell-Based Therapies in Melanoma;International Journal of Molecular Sciences;2024-09-12

3. Pharmacological management of chronic lymphocytic leukemia: current and emerging therapies;Expert Opinion on Pharmacotherapy;2024-09-08

4. Bispecific T-Cell Engagers (BiTEs) in Immunotherapy;Advances in Medical Diagnosis, Treatment, and Care;2024-08-28

5. Cytokine-induced killer cells: new insights for therapy of hematologic malignancies;Stem Cell Research & Therapy;2024-08-13